MaxCyte (MXCT)
(Delayed Data from NSDQ)
$4.49 USD
+0.03 (0.67%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $4.52 +0.03 (0.67%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MXCT 4.49 +0.03(0.67%)
Will MXCT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MXCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MXCT
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
MXCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
Qiagen (QGEN) Surpasses Q2 Earnings and Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates
Other News for MXCT
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
MaxCyte Releases Key Annual Report for 2023
Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT)
MaxCyte Awards Stock Options and RSUs to Directors
MaxCyte AGM Concludes with Positive Outcomes